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Acinar-to-ductal metaplasia (ADM) results from pancreatic injury or KRAS activation, and is an early step in
pancreatic cancer progression. In this issue of Cancer Cell, Ardito and colleagues and Navas and colleagues
demonstrate that ADM- and KRAS-driven pancreatic cancer require EGFR signaling, revealing a mechanism
for developmental reprogramming that primes tumorigenesis.Most tissues respond to injuries such as
those induced by toxins, trauma, or infec-
tions through orchestrated cellular pro-
grams that either mitigate further damage
or enable regeneration. One such re-
sponse is the process of metaplasia,
which involves the conversion or replace-
ment of one differentiated cell type with
another in a given tissue. Metaplasia
helps protect tissues as they adjust to
the insult and the resulting changed envi-
ronment and is usually reverted once nor-
mal conditions are reestablished. This
defensemechanism comes with an unfor-
tunate cost. It is becoming increasingly
clear that sustained metaplasia can serve
as an early precursor to malignant trans-
formation in several organs, including
the pancreas, stomach, and lung.
In thepancreas, acuteor chronic inflam-
mation leads to replacement of damaged
acini with duct-like cells, referred to as
acinar-to-ductal metaplasia (ADM) (re-
viewed in Reichert and Rustgi, 2011)
(Figure 1). The relationship between ADM
and pancreatic ductal adenocarcinoma
(PDA) progression has been studied
extensively in genetically engineered
mouse models. In these models, onco-
genic KRASmutation—the earliest known
genetic alteration in human PDA—pro-
motes the focal development of ADM in
the absence of exogenous inducers of
inflammation. Rather than representing
a reversible state, mutant KRAS-express-
ingmetaplastic ducts progress into ductal
precursor lesions known as pancreatic
intraepithelial neoplasias (PanINs), which
gradually acquire additional genetic
changes including CDKN2A and/or TP53
mutation and evolve into PDA. Treatment
of mice with the cholecystokinin analog
cerulein,which induces pancreatic inflam-mation and widespread ADM, greatly
accelerates PanIN formation and progres-
sion to PDA when KRAS mutations are
present. Thus, it is thought that activated
KRAS locks cells that have undergone
ADM in the ductal state, preventing resto-
ration of normal differentiation, and cre-
ating a reservoir of cells susceptible to
additional oncogenic changes.
The first clues suggest a role for the
epidermal growth factor receptor (EGFR)
pathway in ADM came from transgenic
mouse models in which overexpression
of the EGFR ligand, TGFa, in the pancreas
caused spontaneous ADM and pro-
gressive pancreatic tumorigenesis when
crossed to KRAS, TP53, or CDKN2A mu-
tant strains (Reichert and Rustgi, 2011).
In vitro experiments using pancreatic
explants showed that EGFR activation
could act cell-autonomously in converting
acinar cells into metaplastic ducts (Means
et al., 2005; Miyamoto et al., 2003). The
physiological relevance of this pathway
has now been established in two new
studies by Ardito et al. (2012) and Navas
et al. (2012) in this issue of Cancer Cell.
They employed genetic and pharmaco-
logical inactivation of EGFR in KRAS-
driven mouse models to directly deter-
mine the contribution of endogenous
EGFR pathway signaling to the develop-
ment of ADM and PDA. Consistent with
prior studies, they found that EGFR
expression is upregulated in ADM and
PanIN lesions in these models and in
human pancreatitis specimens. Knockout
of EGFR in the pancreas or treatment of
mice with pharmacological EGFR inhibi-
tors suppressed ADM provoked by acti-
vated KRAS or by cerulein. Moreover,
acute EGFR inhibition resulted in apo-
ptosis in established ADM and PanINCancer Cell 22, Selesions. Importantly, Navas et al. (2012)
found that EGFR knockout completely
prevented PDA development in their
KRAS model even in the context of dele-
tion of CDKN2A, whereas both groups
found that EGFR deletion delayed but
did not eliminate PDA formation in
KRAS-TP53 mutant models. Together,
these results establish that EGFR is
required for both the initiation and survival
of ADM (and PanIN) lesions and show that
its ablation restricts the development of
PDA. KRAS mutations are also early initi-
ating lesions in lung cancer and are
present as later alterations in intestinal
cancer. Thus, it is striking that Navas
et al. (2012) found that EGFR deletion
had no effect on tumorigenesis in KRAS-
driven mouse models of these malignan-
cies. Therefore, rather than playing a
generic function in KRAS-mediated trans-
formation, EGFR has specific roles in
PDA initiation, acting to facilitate the
developmental reprogramming of pan-
creatic acinar cells.
How does EGFR promote ADM?
Although this remains incompletely un-
derstood, there are some intriguing leads.
First, among the EGF family ligands (e.g.,
EGF, TGFa, and AREG), TGFa is uniquely
induced during ADM both in vitro and
in vivo and appears to be the main medi-
ator of ADM. Accordingly, deletion of
ADAM17, which cleaves and activates
TGFa and AREG, blocks ADM to a similar
extent as EGFR deletion, whereas prior
studies have found that AREG fails to
recapitulate the ADM phenotypes in-
duced by TGFa (Wagner et al., 2002).
TGFa is notable for its ability to cause re-
cycling of the receptor back to the cell
surface, thereby allowing for sustained
moderate levels of signaling (von Zastrowptember 11, 2012 ª2012 Elsevier Inc. 281
Figure 1. Role of EGFR Signaling in PDA Initiation and Progression
(A) Exocrine pancreas: acinar cells produce and secrete digestive enzymes, while ductal cells form channels that transport acinar secretions into the intestinal
tract. Centroacinar cells lie at the interface between acinar and ductal cells and may have progenitor-like properties.
(B) Models of PDA progression: following injury, acinar cells undergo acinar-to-ductal metaplasia (ADM), a process that is normally reversible following resolution
of the tissue damage. Activating KRASmutation (KRAS*), the earliest oncogenic alteration in PDA pathogenesis, can also induce ADMwhile preventing reversion
to acinar differentiation. ADM lesions can progress to pancreatic intraepithelial neoplasia (PanIN), which in turn gives rise to PDA following loss of the CDKN2A
and/or TP53 tumor suppressors. EGFR signaling is required both for the initiation of ADM as well as for the survival of cells within established ADM and PanIN
lesions. PDA may also originate from pancreatic duct cells and presumed pancreatic progenitors.
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Previewsand Sorkin, 2007), whereas other EGFR
ligands can be more potent EGFR activa-
tors but induce receptor downregulation.
Hence, the selective role for ADAM17-
TGFa-EGFR axis in ADM and tumor initia-
tion suggests that a sustained threshold
of EGFR activity is required for these
processes. How EGFR and TGFa expres-
sion are induced in this context remains to
be defined.
The signaling pathways downstream of
EGFR that mediate ADM are less clear.
Ardito et al. (2012) show that acute
EGFR inhibition reduced levels of phos-
pho-ERK1/2 and GTP-bound active RAS
in ADM lesions in KRAS mice and acinar
explants, respectively. However, Navas
et al. (2012) did not observe changes in
ERK1/2 activity in their model. Differences
between the mouse models used in these
two studies may account for some of
these discrepancies. Further studies will
be required to fully define the proximal
effectors of EGFR signaling and associ-
ated biochemical mechanisms that facili-
tate ADM. In terms of more downstream
pathways, prior reports have provided
evidence that induction of Notch tran-
scriptional activity contributes to ADM
in vitro in response to TGFa-EGFR sig-
naling (Miyamoto et al., 2003), and thus
Notch warrants additional analysis as
a potential effector of endogenous EGFR
in ADM in vivo.
Does EGFR also contribute to the
malignant growth of established PDA?
Activated EGFR is detected in a subset
of human PDAs, and EGFR inhibition
shows efficacy in some patient-derived
PDA xenografts and PDA cell lines282 Cancer Cell 22, September 11, 2012 ª20(Jimeno et al., 2008). However, Erlotinib
provided only limited benefit when
combined with gemcitabine in a clinical
trial with unselected PDA patients (Moore
et al., 2007) and when administered at ad-
vanced stages in the KRAS-TP53 mouse
model. This suggests that advanced
PDA may have reduced dependence on
EGFR signaling as compared to earlier
stage lesions. Further studies will be
required to ascertain how later stage
cancers escape EGFR dependency and
conversely to identify a molecular signa-
ture for those that remain EGFR-depen-
dent. One such signature may involve
loss of epithelial gene expression,
because Ardito et al. (2012) found that
EGFR expression is extinguished in poorly
differentiated PDA. Moreover, published
studies demonstrate that PDA cell lines
showing mesenchymal features are rela-
tively resistant to erlotinib as compared
to well-differentiated PDA lines (Collisson
et al., 2011).
PDA is the fourth most common cause
of cancer deaths in the United States
with a 5 year survival rate under 5%. Exist-
ing clinical trials with conventional and
targeted therapies have only modest
effects on patient outcomes, and hence
new approaches to disease management
are urgently needed. Since inherited pre-
disposition to chronic pancreatitis greatly
increases PDA risk and precursor lesions
harboring KRAS mutations are common
in otherwise normal pancreatic tissue of
elderly individuals, there may be a benefit
in the development of preventative strate-
gies that eradicate ADM and PanIN
lesions. The present studies support the12 Elsevier Inc.potential of targeting TGFa-ADAM17-
EGFR axis as an approach to PDA
prevention.
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